Reduction in Symptomatic Esophageal Stricture Formation



Status:Completed
Healthy:No
Age Range:18 - 89
Updated:2/15/2017
Start Date:March 2014
End Date:February 2015

Use our guide to learn which trials are right for you!

Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial.

Complete endoscopic resection of early neoplastic BE is a curative procedure. However, a
significant proportion of patients develop symptomatic esophageal strictures following CBE,
and this limits the technique, particularly for circumferential and longer segment disease.
Oral steroid therapy may reduce stricture formation; thereby allowing CBE to be performed
with minimal associated morbidity.

The main objective of the proposed randomized trial is to compare the rate of symptomatic
oesophageal strictures in patients receiving placebo versus oral prednisone.

Inclusion Criteria:

1. Histologically confirmed Barretts mucosa with high grade dysplasia or early
esophageal adenocarcinoma (T1a, intramucosal adenocarcinoma).

2. Barretts segment ≥ 30% circumference, ≤C3 and ≤M5.

3. The general health condition of the patient permits anesthesia for endoscopy.

4. Patient is 18 years of age or older.

5. Informed consent is obtained

Exclusion Criteria:

1. Previous (referral) biopsies show low grade dysplasia only, or invasive
adenocarcinoma.

2. Barretts segment <30% circumference, >C3 or >M5.

3. During initial gastroscopy there are highly suspicious areas for submucosal invasive
cancer (Kudo pit pattern type V; excavated/depressed type morphology; large smooth or
ulcerated nodule). In cases of significant doubt, initial resection is of the highly
suspicious area only, and urgent histology processing requested. If submucosal
invasion is excluded, the patient is rebooked for 1st stage complete barrett's
excision (60% circumferential resection) and randomization after a 4-6 weeks
interval.

4. Presence of a tight peptic oesophageal stricture that impedes safe and effective
endoscopic mucosal resection using a cap (Cook Medical).

5. Active malignancy, uncontrolled Diabetes Mellitus, active or untreated major
psychiatric disorder, uncontrolled infection, uncontrolled hypertension, uncontrolled
or severe congestive cardiac failure, non-correctable coagulopathy (INR>2, or
platelet count <60 x 109/L), osteoporosis, recent peptic ulcer disease,
moderate-to-severe glaucoma or untreated glaucoma, or pregnancy.

6. Unable to provide informed consent

7. Allergy to compound used in tablet formulation
We found this trial at
1
site
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Principal Investigator: Robert Hawes, MD
Phone: 407-303-5503
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials